ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This pilot study assessed the feasibility and impact of continuous glucose monitoring (CGM) in 9 adolescents with T2D. CGM use lowered HbA1c by up to 3.8% in participants who consistently used the device.Comment: Large cohort studies investigating complications in children and adolescents with T2D have clearly shown a higher incidence of complications compared to both adults with T2D and children with type 1 diabetes (T1D). These complicat...

Brief Summary: This meta-analysis including 415 children and adolescents with T2D showed that GLP-1 receptor agonists reduced HbA1c by 1%, fasting blood glucose, and body weight by 1.6 kg, with no notable impact on blood pressure. An increased incidence of mainly gastrointestinal side effects was observed.Comment: Over the past decade, glucagon-like peptide 1 (GLP-1) receptor agonists have revolutionized the management of T2DM in adults.1 Thes...

Brief Summary: This double-blind, placebo-controlled international trial, randomized overweight and obese adults with T2D to either once-weekly subcutaneous Tirzepatide (10 mg or 15 mg) or placebo for 72 weeks. Tirzepatide led to weight reductions of -9.6% with the 10 mg dose and -11.6% with the 15 mg dose, compared to placebo. From a mean baseline 8.0%, HbA1c reduced by –2·1% with both the 10 mg, and 15 mg dose of triszepatied compared to 0·5% reduction on plac...